A new breakout, a two month wait, and now an app that can write the first prescription. What Utah allowed on October 5, 2026, how the AI picks a cream, the real guardrails, the honest limits, and four things you can do.

The nurse taps your arm and says, let's try the other side. On August 19, 2026, the FDA authorized a robot to take that turn. How it works, what the evidence shows, the honest limits, and four things you can do at your next blood draw.

In 1922 Elizabeth Hughes trusted her life to insulin, a medicine nobody could describe. In 1955 Fred Sanger read it, letter by letter: 51 amino acids in one exact order. The story, the honest limits, and two ideas you can use.

In 1953 Vincent du Vigneaud’s team built oxytocin, the first peptide hormone made by chemists. In new mothers it could not be told apart from the real hormone. The story, the honest limits, and two ideas you can use.

In January 1922, Leonard Thompson, 14 and 65 pounds, became the first person treated with insulin. His first shot failed; twelve days later a purer extract worked. Here is the story, Elizabeth Hughes, the honest limits, and two habits that help your insulin.

In 1902, peptides were born twice: Emil Fischer named them in Berlin, and Bayliss and Starling found secretin, the first hormone, in London. Here is the story, its honest limits, and one thing to try at your next meal.

The 2026 Nobel Prize in Medicine began with a green alga that swims toward light. Here is how optogenetics works, what it did for one blind man, its honest limits, and what you can do for your brain today.

If you or a parent is frail, you may worry a weight-loss drug could make things worse. A new analysis of 17,604 heart patients found frailty was more likely to improve on semaglutide. Here are the results, the caveats, and how to protect strength.

A large new trial swapped two rounds of intense chemo for an immune drug called blinatumomab in 709 children with high-risk leukemia. Here are the results, the trade-offs, what it could mean, and three questions to bring to the care team.

One blood test that looks for many cancers at once just had its first large randomized trial. Here is what it found, the drawbacks that matter, what it could mean in the future, and three questions to bring to your next visit.

More than half of healthy adults in the REACT study already had plaque in their arteries, and risk calculators missed most of it. Here is what the study found, what it does not prove, and the three questions I would bring to your next visit.

Most cholesterol panels skip lipoprotein(a), an inherited heart risk marker. Here is what a new Lancet study of Kylo-11 found, what it does not prove yet, and how to ask for the Lp(a) lab at ThriveMed.